TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

5 Stocks Under $10 That Could Rocket Higher Soon
VIDEO

5 Stocks Under $10 That Could Rocket Higher Soon

PRESS RELEASES

Onconova Therapeutics, Inc. Announces Proposed Public Offering Of Common Stock

PRESS RELEASES

Onconova Therapeutics, Inc. To Present At NobleCon17 Virtual Event

PRESS RELEASES

Onconova Therapeutics, Inc. Announces $8.7 Million Public Offering

PRESS RELEASES

Onconova Therapeutics Announces FDA Permission For Study To Proceed Under Its Investigational New Drug Application For Multi-kinase CDK4/6 Inhibitor ON 123300

PRESS RELEASES

Onconova Therapeutics Files Investigational New Drug Application For Multi-kinase CDK4/6 Inhibitor ON 123300

PRESS RELEASES

Onconova Therapeutics To Provide Corporate Update And Third Quarter 2020 Financial Results On November 12, 2020

PRESS RELEASES

Onconova Therapeutics To Present Update During The 2020 BIO Investor Forum Digital Event

PRESS RELEASES

Onconova Therapeutics Announces Initiation Of A Phase 1 Clinical Trial Of ON 123300 In China By Partner HanX Biopharmaceuticals

PRESS RELEASES

Onconova Therapeutics Announces Participation At Upcoming Virtual Events

PRESS RELEASES

Onconova Therapeutics Announces Election Of James J. Marino, JD, MBA As Chairman Of The Board Of Directors

PRESS RELEASES

Onconova Therapeutics Announces Compliance With Nasdaq Bid Price Requirement

PRESS RELEASES

Onconova Therapeutics Announces That The Required Number Of Survival Events Has Been Reached for The Pivotal Phase 3 INSPIRE Trial Data Analysis

PRESS RELEASES

Onconova Therapeutics Submits Application For Rigosertib To Participate In Federally Funded Human Studies In COVID-19 Disease

PRESS RELEASES

Onconova Therapeutics Announces Publication Of Preclinical Data Supporting Rigosertib's Mechanism Of Action As A Targeted Anticancer Therapy

PRESS RELEASES

Onconova Therapeutics Announces Publication Of Phase 1 Results In Leukemia Research Exploring Oral Rigosertib In Combination With Azacitidine In Higher-Risk MDS

PRESS RELEASES

Onconova Therapeutics Announces Participation In Noble Capital Markets Investor Webinar

PRESS RELEASES

Onconova Therapeutics Announces The Initiation Of A Phase 1/2a Study Of Rigosertib Plus Nivolumab For The Treatment Of KRAS Lung Adenocarcinoma

PRESS RELEASES

Onconova Therapeutics Announces Presentation At The 25th Congress Of The European Hematology Association (EHA)

PRESS RELEASES

Onconova Therapeutics Announces Presentation At BIO Digital 2020

PRESS RELEASES

Onconova Therapeutics Announces Virtual Format For 2020 Annual Meeting Of Stockholders

PRESS RELEASES

Onconova Therapeutics To Provide Corporate Update and First Quarter 2020 Earnings On May 14, 2020

PRESS RELEASES

Onconova Therapeutics Strengthens Board Of Directors With Nomination Of Life Sciences Industry Veteran

PRESS RELEASES

Onconova Therapeutics To Provide Corporate Update And Full Year 2019 Financial Results

PRESS RELEASES

Onconova Therapeutics Regains Rigosertib Rights In Greater China